Second-line weekly paclitaxel in patients with inoperable non-small cell lung cancer who fail combination chemotherapy with cisplatin

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Gianfranco BuccheriCuneo Lung Cancer Study Group

Abstract

This phase II study was designed to assess single-agent paclitaxel (Taxol), as second-line chemotherapy. pathological diagnosis of inoperable non-small cell lung cancer (NSCLC) relapsing or refractory to standard front-line platinum (P)-based chemotherapy, performance status < or = 3, normal lab tests, informed consent. Ineligibility criteria: history of second or third cancer (unless surgically cured), mental instability or impairment, pre-existing moderate/severe peripheral neuropathy, previous chemotherapy non-including cisplatin, and previous second-line chemotherapy. Paclitaxel was given by intravenous infusion at a dose of 100 mg/m2 every week, until completion of the treatment plan of 21 weeks, disease progression, persistent toxicity, or patient refusal. Thirty-eight patients (32 males) entered the study; median age was 63 years (range 44-74); cell types were: adenocarcinoma (20), squamous (14), large cell (4). Previous chemotherapies: P and vinorelbine (31 patients) and P, mitomycin C and vinblastine (7 subjects), followed by 21 objective responses. Two patients had one course of paclitaxel; six other patients had early treatment suspensions. The median number of weekly infusions was 12 (range 1-21); median dose-intens...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Jan 1, 1981·Cancer·A B MillerA Winkler
Aug 1, 1997·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·G Buccheri, D Ferrigno
Aug 30, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·D Ferrigno, G Buccheri
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Feb 15, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·George KoumakisAnna P Efremidis
Mar 21, 2002·Expert Review of Molecular Diagnostics·G Buccheri, D Ferrigno
Jun 12, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·J P SculierUNKNOWN European Lung Cancer Working Party
Dec 25, 2002·Japanese Journal of Clinical Oncology·Oscar JuanVicente Alberola
Dec 31, 2002·Critical Reviews in Oncology/hematology·Vicente AlberolaOscar Juan

❮ Previous
Next ❯

Citations

Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H Q HuangG Fleming
Dec 20, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Fabrice BarlésiJean-Louis Pujol
Jan 8, 2010·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Motoshi IchikawaHiroyuki Taniguchi
May 3, 2007·British Journal of Cancer·T BerghmansUNKNOWN European Lung Cancer Working Party
May 6, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Guilherme Z RochaJosé B C Carvalheira

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.